These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7534858)

  • 61. Development and significance of zidovudine resistance in children infected with human immunodeficiency virus.
    Ogino MT; Dankner WM; Spector SA
    J Pediatr; 1993 Jul; 123(1):1-8. PubMed ID: 8100579
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy.
    Semple M; Loveday C; Weller I; Tedder R
    J Med Virol; 1991 Sep; 35(1):38-45. PubMed ID: 1940882
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Quantification of low levels of human immunodeficiency virus (HIV) type 1 RNA in P24 antigen-negative, asymptomatic, HIV-positive patients by PCR.
    Muñoz-Fernández MA; Navarro J; Montes MG; Cosín J; Zabay JM; Fernández-Cruz E
    J Clin Microbiol; 1996 Feb; 34(2):404-8. PubMed ID: 8789024
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Molecular aspect of HIV-1 resistance to zidovudine and its reversal.
    Camsonne R; Bigot MC; Bustany P; Pottier D; Vergnaud M
    Trends Pharmacol Sci; 1994 May; 15(5):137-8. PubMed ID: 7538701
    [No Abstract]   [Full Text] [Related]  

  • 65. p24 antigenaemia and clinical response to zidovudine therapy.
    Montroni M; Silvestri G; Butini L; Regnery C; Bartocci C; Buffarini F; Danieli G
    AIDS; 1993 Mar; 7(3):434-5. PubMed ID: 8471208
    [No Abstract]   [Full Text] [Related]  

  • 66. Anti-V3 loop spectrotype in HIV-infected individuals during zidovudine therapy.
    Biselli R; Del Bono V; Anselmo M; Canessa A; Mazzarello G; D'Amelio R; Bassetti D
    Infection; 1996; 24(3):227-33. PubMed ID: 8811360
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transmission of zidovudine-resistant HIV-1.
    Sönnerburg A; Johansson B; Ayehunie S; Julander I
    AIDS; 1993 Dec; 7(12):1684-5. PubMed ID: 8286086
    [No Abstract]   [Full Text] [Related]  

  • 68. HIV-associated dementia: Prompt response to zidovudine.
    Hoogland ICM; Portegies P
    Neurol Clin Pract; 2014 Jun; 4(3):263-265. PubMed ID: 29473585
    [No Abstract]   [Full Text] [Related]  

  • 69. Estimating HIV-1 fitness characteristics from cross-sectional genotype data.
    Gopalakrishnan S; Montazeri H; Menz S; Beerenwinkel N; Huisinga W
    PLoS Comput Biol; 2014 Nov; 10(11):e1003886. PubMed ID: 25375675
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS.
    Marconi VC; Grandits G; Okulicz JF; Wortmann G; Ganesan A; Crum-Cianflone N; Polis M; Landrum M; Dolan MJ; Ahuja SK; Agan B; Kulkarni H;
    PLoS One; 2011; 6(5):e17956. PubMed ID: 21625477
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments.
    Mbori-Ngacha D; Richardson BA; Overbaugh J; Panteleeff DD; Nduati R; Steele M; John-Stewart G
    J Virol; 2003 Jul; 77(13):7702-5. PubMed ID: 12805473
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure.
    Kijak GH; Simon V; Balfe P; Vanderhoeven J; Pampuro SE; Zala C; Ochoa C; Cahn P; Markowitz M; Salomon H
    J Virol; 2002 Jul; 76(14):7000-9. PubMed ID: 12072500
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Measuring sexual behaviour: methodological challenges in survey research.
    Fenton KA; Johnson AM; McManus S; Erens B
    Sex Transm Infect; 2001 Apr; 77(2):84-92. PubMed ID: 11287683
    [No Abstract]   [Full Text] [Related]  

  • 74. Antiretroviral Drug Resistance in HIV-1.
    Hanna GJ; D'Aquila RT
    Curr Infect Dis Rep; 1999 Aug; 1(3):289-297. PubMed ID: 11095801
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Virus phenotype switching and disease progression in HIV-1 infection.
    Callaway DS; Ribeiro RM; Nowak MA
    Proc Biol Sci; 1999 Dec; 266(1437):2523-30. PubMed ID: 10693824
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Comparison of human immunodeficiency virus type 1 (HIV-1) protease mutations in HIV-1 genomes detected in plasma and in peripheral blood mononuclear cells from patients receiving combination drug therapy.
    Koch N; Yahi N; Ariasi F; Fantini J; Tamalet C
    J Clin Microbiol; 1999 May; 37(5):1595-7. PubMed ID: 10203532
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Managing resistance to anti-HIV drugs: an important consideration for effective disease management.
    Vandamme AM; Van Laethem K; De Clercq E
    Drugs; 1999 Mar; 57(3):337-61. PubMed ID: 10193687
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Antibiotic resistance: an increasing problem?. It always has been, but there are things we can do.
    Hart CA
    BMJ; 1998 Apr; 316(7140):1255-6. PubMed ID: 9554890
    [No Abstract]   [Full Text] [Related]  

  • 79. Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy.
    Tedder RS; Kaye S; Loveday C; Weller IV; Jeffries D; Norman J; Weber J; Bourelly M; Foxall R; Babiker A; Darbyshire JH
    J Clin Microbiol; 1998 Apr; 36(4):1056-63. PubMed ID: 9542937
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS.
    Wilkinson ID; Lunn S; Miszkiel KA; Miller RF; Paley MN; Williams I; Chinn RJ; Hall-Craggs MA; Newman SP; Kendall BE; Harrison MJ
    J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):477-82. PubMed ID: 9343127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.